Revolutionary Immunotherapy Treatment for Glioblastoma Unveiled by Salk Scientists
Scientists at the Salk Institute have discovered that the immunotherapy treatment anti-CTLA-4 leads to significantly greater survival rates in mice with glioblastoma, the most common and deadly form of brain cancer. The treatment relies on CD4+ T cells infiltrating the brain and triggering the tumor-destructive activities of microglia, immune cells that reside in the brain. This finding highlights the potential of harnessing the body's own immune cells to fight brain cancer and could lead to more effective immunotherapies for treating glioblastoma in humans.
